Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Duodenal Neoplasms 1Colorectal Neoplasms 1Barrett Esophagus 1Attenuated familial adenomatous polyposis 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Bevacizumab 55Cetuximab 52Fluorouracil 45Oxaliplatin 39Leucovorin 38pembrolizumab 34Specimen Handling 29Irinotecan 24Magnetic Resonance Spectroscopy 18Biopsy 18Nivolumab 17Capecitabine 14trifluridine tipiracil drug combination 13HMPL-013 13Folfox protocol 13Panitumumab 12Gemcitabine 12Cisplatin 12Carboplatin 11encorafenib 9balstilimab 9Standard of Care 9Pemetrexed 9IFL protocol 9Trifluridine 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × obeticholic acid × 90 days × Clear all
NCT05223036 2026-05-14

Testing Obeticholic Acid for Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled
Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡